Anmelden Kostenlos registrieren

Last updated: 9 June 2023 at 4:27pm EST

Erin Lavelle Net Worth



Ms. Lavelle NLTX stock SEC Form 4 insiders trading

Erin has made over 1 trades of the Neoleukin Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 1,434 units of NLTX stock worth $19,603 on 23 April 2019.

The largest trade she's ever made was selling 1,434 units of Neoleukin Therapeutics stock on 23 April 2019 worth over $19,603. On average, Erin trades about 239 units every 0 days since 2018. As of 23 April 2019 she still owns at least 4,408 units of Neoleukin Therapeutics stock.

You can see the complete history of Ms. Lavelle stock trades at the bottom of the page.





Erin Lavelle biography

Erin M. Lavelle serves as Director of the Company. Ms. Lavelle joined Alder in April 2018 to focus on operational initiatives preparing the company for its first product launch. Prior to Alder, she held a variety of roles during 15 years at Amgen Inc. In her last role at Amgen, she served as General Manager of Amgen's Taiwan affiliate. Prior to that role, Ms. Lavelle was based in Hong Kong as an Executive Director for the Japan Asia-Pacific region, leading Commercial Excellence and Digital Health. Before her time in Asia, she held roles as an Executive Director in the areas of Global Marketing, Global Commercial Finance, and Strategy & Corporate Development. Ms. Lavelle began her career in 1998 as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle holds a Bachelor of Arts in Economics from Yale University.



How old is Erin Lavelle?

Erin Lavelle is 42, she's been the Director of Neoleukin Therapeutics since 2020. There are 9 older and 2 younger executives at Neoleukin Therapeutics. The oldest executive at Neoleukin Therapeutics, Inc. is Lewis Williams, 70, who is the Independent Director.

What's Erin Lavelle's mailing address?

Erin's mailing address filed with the SEC is C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE, WA, 98102.

Insiders trading at Neoleukin Therapeutics

Over the last 5 years, insiders at Neoleukin Therapeutics have traded over $425,653 worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth $38,477,971 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... und Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $593,084. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth $1,462,619.



What does Neoleukin Therapeutics do?

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.



What does Neoleukin Therapeutics's logo look like?

Neoleukin Therapeutics, Inc. logo

Neoleukin Therapeutics executives and stock owners

Neoleukin Therapeutics executives and other stock owners filed with the SEC include: